Plasminogen activator inhibitor 1 in thrombotic disease

Current Opinion in Hematology

Volumn 3, Issue 5, 1996, Pages 372-378

  Wiman, Björn ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

BLOOD CLOT LYSIS; DEEP VEIN THROMBOSIS; FIBRINOLYSIS; HUMAN; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE THROMBOSIS; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOSIS;

EID: 0029829819     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199603050-00007     Document Type: Review

References (64)

1. Chmielewska J, Rȧnby M, Wiman B: Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983, 31:427-436.
2. Kruithof EKO, Tran-Thang C, Ransijn A, Bachmann F: Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984, 64:907-913.
3. Chmielewska J, Rȧnby M, Wiman B: Kinetics of the inhibition of plasminogen activators by the plasminogen-activator inhibitor. Evidence for 'second-site' interactions. Biochem J 1988, 251:327-332.
4. 2-antiplasmin complex in plasma: a global fibrinolytic assay [abstract no 1958]. Thromb Haemost 1993, 69:1091.
5. Pedersen OD, Gram J, Jespersen J: Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease. Thromb Haemost 1995, 73:835-840.
6. Andreotti F, Davies GJ, Hackett DR, Khan MI, de Bart AC, Aber VR, Maseri A, Kluft C: Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am J Cardiol 1988, 62:635-637.
7. Grimaudo V, Hauert J, Bachmann F, Kruithof EKO: Diurnal variation of the fibrinolytic system. Thromb Haemost 1988, 59:495-499.
8. Angelton P, Chandler WL, Schmer G: Diurnal variation of tissue-type plasminogen activator and its rapid inhibition. Circulation 1989, 79:101-106.
9. Kluft C, Verheijen JH, The Leiden Fibrinolysis Working Party: Blood collection and handling procedures for assessment of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1). Fibrinolysis 1990, 4:155-161.
10. Wiman B, Hamsten A: Impaired fibrinolysis and risk of thromboembolism. Prog Cardiovasc Dis 1991, 34:179-192.
11. van Meijer M, Pannekoek H: Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update. Fibrinolysis 1995, 9:263-276.
12. Loskutoff DJ, van Mourik JA, Erickson LA, Lawrence D: Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci U S A 1983, 80:2956-2960.
13. Gelehrter TD, Barouski Miller PA, Coleman PL, Cwikel BJ: Hormonal regulation of plasminogen activator in rat hepatoma cells. Mol Cell Biochem 1983, 53-54:11-21.
14. Laug W: Vascular smooth muscle cells inhibit the plasminogen activators secreted by endothelial cells. Thromb Haemost 1985, 53:165-169.
15. Kruithof EKO, Tran-Thang C, Bachman F: Studies on the release of a plasminogen activator inhibitor by human platelets. Thromb Haemost 1986, 55:201-205.
16. Samad F, Yamamoto K, Loskutoff DJ: Distribution and regulation of plasminogen activator inhibitor 1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest 1996, 97:37-46. Production of PAI-1 mRNA in the vessel wall in mice is induced by inflammatory mediators. PAI-1 mRNA was detected in several different cell types including adipocytes.
17. Lundgren CH, Brown SL, Nordt TK, Sobel BE, Fujii S: Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. Circulation 1996, 93:106-110. Both PAI-1 mRNA and protein are produced in adipocytes, which may partly explain the correlation between plasma PAI-1 on one hand, and serum triglycerides or body weight on the other.
18. Chandler WL, Levy WC, Stratton JR: The circulatory regulation of TPA and UPA secretion, clearance, and inhibition during exercise and during the infusion of isoproterenol and phenylephrine. Circulation 1995, 92:2984-2994. An impressive human model to clarify the important metabolic pathways for fibrinolytic compounds.
19. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S: Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb Vasc Biol 1991, 11:183-190.
20. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM: The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993, 268:10739-10745.
21. Colucci M, Paramo JA, Collen D: Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985, 75:818-824.
22. Emeis JJ, Kooistra T: Interleukin-1 and lipopolysaccharide induce a fast-acting inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986, 163:1260-1266.
23. Mellbring G, Dahlgren S, Wiman B: Plasma fibrinolytic activity in patients undergoing major abdominal surgery. Acta Chir Scand 1985, 151:109-114.
24. Eriksson B, Eriksson E, Gyzander E, Teger-Nilsson AC, Thorsen S, Risberg B: Thrombosis after hip replacement, relationship to the fibrinolytic system. Acta Orthop Scand 1989, 60:159-163.
25. Hamsten A, Wiman B, de Faire U, Blombäck M: Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985, 313:1557-1563.
26. Mehta J, Mehta P, Lawson D, Saldeen T: Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 1987, 9:263-268.
27. Juhan-Vague I, Vague P, Alessi M, Badier C, Valadier J, Aillaud M, Atlan C: Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabetes Metab 1987, 13:331-336.
28. Juhan-Vague I, Thompson SG, Jespersen J, On behalf of the ECAT Angina Pectoris Study Group: Involvement of the hemostatic system in the insulin resistance syndrome, a study of 15000 patients with angina pectoris. Arterioscler Thromb 1993, 13:1865-1873.
29. Landin K, Tengborn L, Smith U: Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990, 227:273-278.
30. Landin K, Stiegendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, Smith U: Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 1990, 10:1044-1048.
31. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D: Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by hepatocellular cell line HepG2. Thromb Haemost 1988, 60:491-494.
32. Landin K, Tengborn L, Smith U: Effects of metformin and metoprolol CR on hormones and fibrinolytic variables during a hyperinsulinemic, euglycemic clamp in man. Thromb Haemost 1994, 71:783-787.
33. Juhan-Vague I, Alessi MC, Vague P: Increased plasma plasminogen activator inhibitor-1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991, 34:457-462.
34. Folsom AR, Qamhieh HT, Wing RR, Jeffery RW, Stinson VL, Kuller LH, Wu KK: Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII and other hemostatic factors in moderately overweight adults. Arterioscler Thromb 1993, 13:162-169.
35. Maser RE, Ellis D, Erbey JR, Orchard TJ: Little relationship of plasmino gen activator inhibitor (PAI-1) with complications of insulin-dependent diabetes mellitus: Pittsburgh epidemiology of diabetes complications study. Fibrinolysis 1995, 9:139-144. This paper answers the question whether the increased plasma PAI-1 levels frequently found in diabetic patients are of importance for development of diabetic complications. This is obviously not the case.
36. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS: Determinants of plasminogen activator inhibitor 1 activity in treating NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995, 44.37-42. Among patients with non-insulin-dependent diabetes plasma PAI-1 levels correlate much stronger with serum triglycerides in the group who are homozygous for the 4G allele in the PAI-1 promoter region, as compared with the groups of the other genotypes regarding this polymorphism.
37. Sundell IB, Dahlgren S, Rȧnby M, Lundin E, Stenling R, Nilsson TK: Reduction of elevated plasminogen activator inhibitor levels during modest weight loss. Fibrinol 1989, 3:51-53.
38. Mehrabian M, Peter JB, Barnard RJ, Lusis AJ: Dietary regulation of fibrinolytic factors. Atherosclerosis 1990, 84:25-32.
39. Schulman S, Lindmarker P, Johnsson H: Influence of changes in lifestyle on fibrinolytic parameters and recurrence rate in patients with venous thromboembolism. Blood Coagul Fibrinol 1995, 6:311-316. The plasma PAI-1 concentration can be gradually decreased as a result of changes in lifestyle, including dietary changes, increase in physical activity, and weight loss.
40. Fujii S, Sobel BE: Direct effects of gemfibrozil on the fibrinolytic system. Diminution of synthesis of plasminogen activator inhibitor type 1. Circulation 1992, 85:1888-1893.
41. Bröijersen A, Eriksson M, Wiman B, Angelin B, Hjemdahl P: Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels. Arterioscler Thromb Vasc Biol 1996, 16:511-516. A very well-controlled study on the effect of gemfibrozil on the plasma lipoproteins and fibrinolytic compounds. No changes whatsoever were found for the fibrinolytic factors.
42. Loskutoff DJ, Linders M, Keijer J, Veerman H, van Heerikhuizen H, Pannekoek H: Structure of the human plasminogen activator inhibitor 1 gene: nonrandom distribution of introns. Biochemistry 1987, 26:3763-3768.
43. Strandberg L, Lawrence D, Ny T: The organization of the human-plasminogen-activator-inhibitor-1 gene. Implications on the evolution of the serine-protease inhibitor family. Eur J Biochem 1988, 176:609-616.
44. van Hinsbergh VW, Kooistra T, van den Berg EA, Princen HM, Fiers W, Emeis JJ: Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 1988, 72:1467-1473.
45. Klinger KW, Winqvist R, Riccio A, Andreasen PA, Sartorio R, Nielsen LS, Stuart N, Stanislovitis P, Watkins P, Douglas R, Grzeschik KH, Alitalo K, Blasi F, Dane K: Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis. Proc Natl Acad Sci U S A 1987, 84:8548-8552.
46. Falk G, Almqvist Ȧ, Nordenhem A, Svensson H, Wiman B: Allele-specific PCR for detection of a sequence polymorphism in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) gene. Fibrinolysis 1995, 9:170-174. Development of a reliable polymerase chain reaction method for genotyping the 4G/5G polymorphism in the PAI-1 promoter region. An age-dependent difference in the genotype distribution regarding this polymorphism was found.
47. Schulman S, Wiman B, for the Duration of Anticoagulation (DURAC) Trial Study Group: The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Thromb Haemost 1996, 75:607-611.
48. Angles Cano E, Gris JC, Loyau S, Schved JF: Familial association of high levels of histidine-rich glycoprotein and plasminogen activator inhibitor-1 with venous thromboembolism. J Lab Clin Med 1993, 121:646-653.
49. Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR: Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 1990, 346:74-76.
50. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van-den-Oord JJ, Collen D, Mulligan RC: Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994, 368:419-424.
51. Paramo JA, Alfaro MJ, Rocha E: Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fast-acting inhibitor: relationship to deep vein thrombosis and influence of prophylaxis. Thromb Haemost 1985, 54:713-716.
52. Mellbring G, Dahlgren S, Wiman B, Sunnegárd O: Relationship between preoperative status of the fibrinolytic system and occurrence of deep vein thrombosis after major abdominal surgery. Thromb Res 1985, 39:157-163.
53. Hamsten A, de Faire U, Walldius G, Dahlén G, Szamosi A, Landou C, Blombäck M, Wiman B: Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987, 2:3-9.
54. Jansson JH, Nilsson TK, Olofsson BO: Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991, 12:157-161.
55. Jansson JH, Olofsson BO, Nilsson TK: Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation 1993, 88:2030-2034.
56. Ridker PM, Vaughan PE, Stampfer MJ, Manson JE, Hennehens CH: Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993, 341:1165-1168.
57. Cortellaro M, Cofrancesco E, Boscheti C, Mussoni L, Donati MB, Cardillo M, Catalano M, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, Pozzoli E, Turri M, for the PLAT Group: Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients: a case-control study. Arterioscler Thromb 1993, 13:1412-1417.
58. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo PJCW, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995, 322:635-641. A very large longitudinal study of angina pectoris patients. Plasma tPA antigen concentrations but not PAI-1 concentrations correlated independently to future cardiovascular events.
59. Eriksson P, Kallin B, van't Hooft FM, Bávenholm P, Hamsten A: Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995, 92:1851-1855. A small study of young patients with myocardial infarction regarding the 4G/5G polymorphism in the PAI-1 promoter region. Presence of the 4G allele was more common in individuals with reinfarction than in those without a second event.
60. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A, Luc G, Cambou JP, Arveiler D, Henney AM, Cambien F: The 4G/5G genetic polymorphism In the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 1995, 74:837-841. In contrast to the study by Eriksson et al. (Proc Natl Acad Sci USA 1995, 92:1851-1855), no correlation between genotype, regarding the 4G/5G polymorphism, and development of myocardial infarction was found in a much larger study of patients included in the Eude Cas-Temoins de l'Infarctus du Myocarde study.
61. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A, Luc G, Cambou JP, Arveiler D, Henney AM, Cambien F: The 4G/5G genetic polymorphism In the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 1995, 74:837-841. In contrast to the study by Eriksson et al. (Proc Natl Acad Sci USA 1995, 92:1851-1855), no correlation between genotype, regarding the 4G/5G polymorphism, and development of myocardial infarction was found in a much larger study of patients included in the Eude Cas-Temoins de l'Infarctus du Myocarde study.
62. Torr-Brown SR, Sobel BE: Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets. Thromb Res 1993, 72:413-421.
63. Stringer HAR, van Swieten P, Heijnen HFG, Sixma JJ, Pannekoek H: Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generate in the chandler loop. Arteriosclerosis Thromb 1994, 14:1452-1458.
64. Biemond BJ, Levi M, Coronel R, Janse MJ, ten Gate JW, Pannekoek H: Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody. Circulation 1995, 91:1175-1181. This is one of several nice studies during the past couple of years demonstrating that platelet PAI-1 is of pathophysiological significance in preventing lysis of a thrombus.